Business Wire

GIANT Protocol Raises $5 Million Seed Round Led by CoinFund

16.12.2021 19:30:00 EET | Business Wire | Press release

Share

GIANT Protocol, a leading-edge web3 protocol to decentralize and democratize access to the internet and financial services, is delighted to announce it has raised USD $5 million in a seed funding round led by pioneer blockchain-focused investment firm, CoinFund, with additional participation from other tier one blockchain investors including Blockchange, Gumi Cryptos, Entheos Ventures, Argonautic Ventures, Bronco Fund. The round was oversubscribed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005703/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GIANT Protocol Team: Left to Right: Merijn Terheggen COO and Co Founder (left), Suruchi Gupta CEO and Founder (center), Jinesh Doshi, Founding Engineer (right) (Photo: Business Wire)

GIANT (Global Internet Access Network Token) Protocol was founded with the objective to launch a decentralized connectivity economy that can address multiple challenges in the telecom industry. The tokenized bandwidth platform will enable anyone with a mobile phone to access the internet and earn rewards based on their connectivity. GIANT Protocol is in an advanced stage of development with an experienced founding team and a well-established network in the telecom sector.

Suruchi Gupta, Co-Founder and CEO of GIANT, commented "At GIANT, we believe internet access is a basic human right and that an Internet that works for everyone can only be built together. We are at the start of our journey, but we are honoured to have received support from tier one investors who fundamentally understand the problem we are solving with GIANT.”

Jake Brukhman, Founder and CEO CoinFund, said “Telco networks have historically been functionally local, yet our lives have become more international and interconnected. Customers are looking for better telecom services experience all over the World. GIANT is moving the world forward by establishing a new global connectivity economy.”

He added: “As a strategic fund, CoinFund is passionate about being the best partner to early-stage blockchain companies. Suruchi is a rising star in the world of technology and she is also working with some of the most seasoned and respected technology leaders in the industry to bring this idea into a practical utility the world over. GIANT has uniquely pledged to convert bandwidth into a digital asset that can be used as a currency and we are pleased to support this innovative team as they continue to develop their Global Internet Access Network Token.”

As part of GIANT’s development, the project has also hired a world-class team of executives hailing from Juniper, Salesforce, HackerOne, Roku, Mobile365, and others. The team has collectively raised $200M+ in the past and has generated $10B+ in value.

Merijn Terheggen, Co-Founder and COO, has extensive experience at building startups. Before joining GIANT as a Co-Founder, Merijn Terheggen cofounded HackerOne and served as its CEO. HackerOne is the leading and still rapidly growing bug bounty platform that has raised $110M in funding, has about 350 employees, and has 2 million hackers that have found and reported hundreds of thousands of serious security vulnerabilities in thousands of large companies, governments, and banks.

Merijn Terheggen, commented: “HackerOne was created from a desire to unite people working on security and unlock the creativity and ingenuity of those trying to get around obstacles. The key for us had always been about community and collaboration, and rewarding creativity and merits. GIANT is taking this philosophy to a whole new level by leveraging blockchain. Where HackerOne aims to empower the world to build a safer internet, GIANT expands this mission by aiming to empower the world to build the digital infrastructure that humanity will need in the coming decades. And of course this infrastructure is decentralized, democratized, accessible to anyone, and owned by everyone. It is an honour to work with Suruchi and the team on this mission.”

ENDS

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rachel McHugh
Rachel@cw8-communications.com

Giant@cw8-communications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye